BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21324834)

  • 1. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act.
    Hecht SS
    Nicotine Tob Res; 2012 Jan; 14(1):18-28. PubMed ID: 21324834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced nicotine product standards for combustible tobacco: building an empirical basis for effective regulation.
    Donny EC; Hatsukami DK; Benowitz NL; Sved AF; Tidey JW; Cassidy RN
    Prev Med; 2014 Nov; 68():17-22. PubMed ID: 24967958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tobacco packaging and labeling policies under the U.S. Tobacco Control Act: research needs and priorities.
    Hammond D
    Nicotine Tob Res; 2012 Jan; 14(1):62-74. PubMed ID: 22039072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permissive nicotine regulation as a complement to traditional tobacco control.
    Sumner W
    BMC Public Health; 2005 Feb; 5():18. PubMed ID: 15730554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policy and health implications of using the U.S. Food and Drug Administration product design approach in reducing tobacco product risk.
    Givel M
    Curr Drug Abuse Rev; 2008 Jun; 1(2):135-41. PubMed ID: 19630712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine reduction revisited: science and future directions.
    Hatsukami DK; Perkins KA; Lesage MG; Ashley DL; Henningfield JE; Benowitz NL; Backinger CL; Zeller M
    Tob Control; 2010 Oct; 19(5):e1-10. PubMed ID: 20876072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Harm reduction strategy in tobacco control].
    Gorini G
    Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tobacco and nicotine product testing.
    Hatsukami DK; Biener L; Leischow SJ; Zeller MR
    Nicotine Tob Res; 2012 Jan; 14(1):7-17. PubMed ID: 21460383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure to Nicotine and Selected Toxicants in Cigarette Smokers Who Switched to Electronic Cigarettes: A Longitudinal Within-Subjects Observational Study.
    Goniewicz ML; Gawron M; Smith DM; Peng M; Jacob P; Benowitz NL
    Nicotine Tob Res; 2017 Feb; 19(2):160-167. PubMed ID: 27613896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research opportunities concerning youth and the Family Smoking Prevention and Tobacco Control Act.
    DiFranza JR
    Nicotine Tob Res; 2012 Jan; 14(1):54-61. PubMed ID: 21975309
    [No Abstract]   [Full Text] [Related]  

  • 11. Anticipating Industry Arguments: The US Food and Drug Administration's Authority to Reduce Nicotine Levels in Cigarettes.
    Berman ML; Zettler PJ; Ashley DL
    Public Health Rep; 2018; 133(4):502-506. PubMed ID: 29879366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research gaps related to tobacco product marketing and sales in the Family Smoking Prevention and Tobacco Control Act.
    Ribisl KM
    Nicotine Tob Res; 2012 Jan; 14(1):43-53. PubMed ID: 21690316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Exposure to Harmful and Potentially Harmful Smoke Constituents With the Tobacco Heating System 2.1.
    Lüdicke F; Baker G; Magnette J; Picavet P; Weitkunat R
    Nicotine Tob Res; 2017 Feb; 19(2):168-175. PubMed ID: 27613951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing surveillance for "modified-risk" tobacco products.
    O'Connor RJ
    Nicotine Tob Res; 2012 Jan; 14(1):29-42. PubMed ID: 21330282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The consequences of the unregulated cigarette.
    Gray N
    Tob Control; 2006 Oct; 15(5):405-8. PubMed ID: 16998176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No sisyphean task: how the FDA can regulate electronic cigarettes.
    Paradise J
    Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measures to control tobacco use: immunity, advertising restrictions, and FDA control as proposed in the failed tobacco settlement.
    Pinto CF
    J Contemp Health Law Policy; 1998; 15(1):307-56. PubMed ID: 9989001
    [No Abstract]   [Full Text] [Related]  

  • 18. Immediate Switching to Reduced Nicotine Cigarettes in a U.S.-Based Sample: The Impact on Cannabis Use and Related Variables at 20 Weeks.
    Meier E; Rubin N; Dermody SS; Tessier KM; Hecht SS; Murphy S; Jensen J; Donny EC; al'Absi M; Drobes D; Koopmeiners J; Denlinger-Apte R; Tidey JW; Vandrey R; Thorne C; Hatsukami D
    Nicotine Tob Res; 2023 Apr; 25(5):867-874. PubMed ID: 36198098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tobacco under the FDA: a summary of the Family Smoking Prevention and Tobacco Control Act.
    Lundeen RE
    Health Care Law Mon; 2009 Sep; 2009(9):2-9. PubMed ID: 19771935
    [No Abstract]   [Full Text] [Related]  

  • 20. Research priorities and infrastructure needs of the Family Smoking Prevention and Tobacco Control Act: science to inform FDA policy.
    Leischow SJ; Zeller M; Backinger CL
    Nicotine Tob Res; 2012 Jan; 14(1):1-6. PubMed ID: 22184581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.